Dawn Cooper
Psychiatric/Mental Health · Tulsa, OKNPI 1669946786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,402 and has fallen 81.7% since, to $256 in 2025.
Across 224 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$870
- Otsuka America Pharmaceutical, Inc.$551
- Alkermes, Inc.$486
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$422
- Lundbeck LLC$381
- Johnson & Johnson$333
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,123100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $870 |
| Otsuka America Pharmaceutical, Inc. | 32 | $551 |
| Alkermes, Inc. | 18 | $486 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $422 |
| Lundbeck LLC | 24 | $381 |
| Johnson & Johnson | 7 | $333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $206 |
| Corium, LLC | 9 | $168 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Neurocrine Biosciences, Inc. | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Sunovion Pharmaceuticals Inc. | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 6 | $95 |
| Idorsia Pharmaceuticals US Inc | 5 | $75 |
| Eisai Inc. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,132 in reported general payments places this provider in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 33 | $794 |
| Mirtazapine | 50 | $719 |
| Sertraline Hcl | 38 | $369 |
| Trazodone Hcl | 59 | $315 |
| Olanzapine | 22 | $159 |
| Risperidone | 13 | $138 |
| Duloxetine Hcl | 11 | $137 |
| Tramadol Hcl | 12 | $125 |
| Lorazepam | 18 | $112 |
| Hydroxyzine Pamoate | 12 | $79 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Tulsa
- Fernanda CooleyTulsa$16K
- Pramila TraxlerTulsa$12K
- Sabrina ConleyTulsa$10K
- la Maria FolksTulsa$10K
- Emily MooreTulsa$9K
- Caroline LeithnerTulsa$7K
- John StanfordTulsa$5K
- Rebekah MackeyTulsa$5K
- Kari MurphyTulsa$5K
- Jordan GillinghamTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.